NSCLCmetastatic non-small-cell lung adenocarcinomapembrolizumabtertiary hospitalImmune checkpoint inhibitorsproton pump inhibitors
… was conducted at a tertiary hospital. Patients with metastatic NSCLC and PD-L1 ≥50% treated with pembrolizumab monotherapy in first-…